文献速递核素与放射性配体治疗肿瘤 PET/CT

67Cu-CuSarTATE肽受体放射性核素治疗对生长抑素阳性神经内分泌肿瘤模型高度有效

Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model.
PubMed 文献 · J Nucl Med · 2020-05-15

本研究在AR42J大鼠胰腺外分泌肿瘤荷瘤小鼠中比较67Cu-CuSarTATE与177Lu-LuTATE的抗肿瘤疗效。单次给药5 MBq后,67Cu-CuSarTATE使肿瘤生长抑制75%,177Lu-LuTATE抑制89%,两者均将生存期从对照组的12天延长至21天。分两次给药(间隔2周)较单次给药显著改善生存。

要点

  • 单次5 MBq 67Cu-CuSarTATE使AR42J肿瘤生长抑制75%,177Lu-LuTATE抑制89%。
  • 67Cu-CuSarTATE与177Lu-LuTATE均将生存期从对照组12天延长至21天。
  • 分两次给药较单次给药显著改善生存:67Cu-CuSarTATE 47 vs 36天(P=0.036),177Lu-LuTATE 46 vs 29天(P=0.040)。

核心结论

  • 67Cu-CuSarTATE在BALB/c裸鼠中耐受良好,对AR42J肿瘤体内高度有效。
  • 67Cu-CuSarTATE和177Lu-LuTATE分为两次、间隔2周给药比单次给药更有效。
  • 67Cu-CuSarTATE在AR42J肿瘤模型中的抗肿瘤活性表明该新型药物适合用于生长抑素受体2表达神经内分泌肿瘤治疗的临床评估。

研究设计与样本

  • 在AR42J(大鼠胰腺外分泌)肿瘤荷瘤小鼠中比较不同剂量67Cu-CuSarTATE与177Lu-LuTATE的抗肿瘤疗效。
  • 第二项研究评估分次给药疗效,比较30 MBq 67Cu-CuSarTATE或177Lu-LuTATE单次静脉注射与两次15 MBq分次(间隔2周)给药。

主要发现

  • 单次给予67Cu-CuSarTATE(5 MBq)7天后,肿瘤生长较溶剂对照抑制75%。
  • 单次给予177Lu-LuTATE(5 MBq)7天后,肿瘤生长抑制89%。
  • 生存期从对照组的12天延长至67Cu-CuSarTATE和177Lu-LuTATE治疗后的21天。
  • 67Cu-CuSarTATE分两次给药较单次给药显著改善生存(47 vs 36天,P=0.036)。
  • 177Lu-LuTATE分两次给药较单次给药显著改善生存(46 vs 29天,P=0.040)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peptide receptor radionuclide therapy (PRRT) using radiolabeled octreotate is an effective treatment for somatostatin receptor 2-expressing neuroendocrine tumors. The diagnostic and therapeutic potential of 64Cu and 67Cu, respectively, offers the possibility of using a single somatostatin receptor-targeted peptide conjugate as a theranostic agent. A sarcophagine cage amine ligand, MeCOSar (5-(8-methyl-3,6,10,13,16,19-hexaaza-bicyclo[6.6.6]icosan-1-ylamino)-5-oxopentanoic acid), conjugated to (Tyr3)-octreotate, called 64Cu-CuSarTATE, was demonstrated to be an imaging agent and potential prospective dosimetry tool in 10 patients with neuroendocrine tumors. This study aimed to explore the antitumor efficacy of 67Cu-CuSarTATE in a preclinical model of neuroendocrine tumors and compare it with the standard PRRT agent, 177Lu-LuDOTA-Tyr3-octreotate (177Lu-LuTATE). Methods: The antitumor efficacy of various doses of 67Cu-CuSarTATE in AR42J (rat pancreatic exocrine) tumor-bearing mice was compared with 177Lu-LuTATE. Results: Seven days after a single administration of 67Cu-CuSarTATE (5 MBq), tumor growth was inhibited by 75% compared with vehicle control. Administration of 177Lu-LuTATE (5 MBq) inhibited tumor growth by 89%. Survival was extended from 12 d in the control group to 21 d after treatment with both 67Cu-CuSarTATE and 177Lu-LuTATE. In a second study, the efficacy of fractionated delivery of PRRT was assessed, comparing the efficacy of 30 MBq of 67Cu-CuSarTATE or 177Lu-LuTATE, either as a single intravenous injection or as two 15-MBq fractions 2 wk apart. Treatment of tumors with 2 fractions significantly improved survival over delivery as a single fraction (67Cu-CuSarTATE: 47 vs. 36 d [P = 0.036]; 177Lu-LuTATE: 46 vs. 29 d [P = 0.040]). Conclusion: This study demonstrates that 67Cu-CuSarTATE is well tolerated in BALB/c nude mice and highly efficacious against AR42J tumors in vivo. Administration of 67Cu-CuSarTATE and 177Lu-LuTATE divided into 2 fractions over 2 wk was more efficacious than administration of a single fraction. The antitumor activity of 67Cu-CuSarTATE in the AR42J tumor model demonstrated the suitability of this novel agent for clinical assessment in the treatment of somatostatin receptor 2-expressing neuroendocrine tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cullinane C, Jeffery CM, Roselt PD, et al. Peptide Receptor Radionuclide Therapy with 67Cu-CuSarTATE Is Highly Efficacious Against a Somatostatin-Positive Neuroendocrine Tumor Model. J Nucl Med. 2020. PMID: 32414949. doi:10.2967/jnumed.120.243543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。